Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis

Part of paid clinical trials in East Hanover, New Jersey.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT05513014
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Secukinumab — DRUG
    Patients with Psoriasis who initiated Secukinumab

Study Details

The study was conducted to describe the demographics, disease characteristics, disease severity, comorbidities and patient reported outcomes at baseline and follow-up periods among adult patients diagnosed with PsO in CorEvitas' PsO Registry under routine medical care initiating secukinumab (SEC).

Key Dates

Start date
Mar 21, 2021
Status verified
Nov 2022
Primary completion
Aug 31, 2021
Completion
Aug 31, 2021

Study Design

Enrollment
1,518 participants (actual)

Arms

  • Arm: Secukinumab: Overall Cohort
    Patients with Psoriasis who initiated Secukinumab
  • Arm: Biologic Experienced
    Patients who had the history of use of ≥1 biologic medication for the treatment of PsO at the time of SEC initiation
  • Arm: Biologic Naive
    Patients who had no history of use of biologic medication for the treatment of PsO at the time of SEC initiation

Primary Outcome Measure

Age [ Time Frame: Baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
Novartis PharmaceuticalsEast HanoverNew Jersey07936-1080-

Find similar trials in East Hanover, NJ

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Novartis Pharmaceuticals· East Hanover, NJ

Related Studies